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We have isolated and characterized a-conotoxin EpI, a
novel sulfated peptide from the venom of the mollus-
civorous snail, Conus episcopatus. The peptide was clas-
sified as an a-conotoxin based on sequence, disulfide
connectivity, and pharmacological target. EpI has ho-
mology to sequences of previously described a-conotox-
ins, particularly PnIA, PnIB, and ImI. However, EpI dif-
fers from previously reported conotoxins in that it has a
sulfotyrosine residue, identified by amino acid analysis
and mass spectrometry. Native EpI was shown to coe-
lute with synthetic EpI. The peptide sequence is consist-
ent with most, but not all, recognized criteria for pre-
dicting tyrosine sulfation sites in proteins and peptides.
The activities of synthetic EpI and its unsulfated ana-
logue [Tyr15]EpI were similar. Both peptides caused
competitive inhibition of nicotine action on bovine ad-
renal chromaffin cells (neuronal nicotinic ACh recep-
tors) but had no effect on the rat phrenic nerve-dia-
phragm (muscle nicotinic ACh receptors). Both EpI and
[Tyr15]EpI partly inhibited acetylcholine-evoked cur-
rents in isolated parasympathetic neurons of rat intra-
cardiac ganglia. These results indicate that EpI and
[Tyr15]EpI selectively inhibit a3b2 and a3b4 nicotinic
acetylcholine receptors.
Cone snail venoms contain complex mixtures of peptides
(conotoxins or conopeptides) that bind with high affinity and
specificity to a diversity of mammalian macromolecular recep-
tors. Targets currently identified include sodium, calcium, and
potassium ion channels and N-methyl-D-aspartate-glutamate,
vasopressin and acetylcholine receptors. Most characterized
bioactive conopeptides contain post-translational modifications
that include carboxylation, hydroxylation, bromination, and
C-terminal amidation (1–3) but modifications such as phospho-
rylation or sulfation have not been demonstrated.
One pharmacological class of conopeptides, the a-conotoxins,
inhibit acetylcholine action at the nicotinic acetylcholine recep-
tor (nAChR).1 The majority of a-conotoxins isolated from fish-
hunting cone snails, including GI, GIA, and GII from Conus
geographus (4), MI from Conus magus (5), and SI and SII from
Conus striatus (6, 7), show extensive structural homology, a
conserved cysteine framework, and target the muscle subtype
of the nAChR. The a-conotoxins PnIA and PnIB from a mollusc-
hunting cone snail, Conus pennaceus (8), and ImI from a worm-
hunting cone snail, Conus imperialis (9) share a similar cys-
teine framework to a-conotoxins from fish-hunting cones, but
have a different sequence pattern and target the neuronal
subtypes of the nAChR. The a-conotoxins MII and EI from
fish-hunting cones resemble the latter group in sequence pat-
tern, but EI targets the muscle-type nAChR (10, 11). The new
aA-conotoxin class, which includes PIVA isolated from the fish-
hunting Conus purpurascens, contains atypical sequences and
a novel cysteine framework (12). The sequence, disulfide con-
nectivity, and specificity of a-conotoxins for mammalian
nAChRs are given in Table I.
The nAChRs are a superfamily of ligand-gated ion channels
that is classified into muscle and multiple neuronal subtypes
(13). The physiological and pharmacological heterogeneity of
neuronal nAChRs is reflected by the diversity of subunit com-
position of these heteropentameric ion channel complexes (14,
15). Neuronal receptors are composed of several possible a
subtypes (a2–a7, a9) and 3 possible b subtypes (b2–b4),
whereas muscle receptors are composed of five subunits a12bed
or a12bgd in mature or embryonic tissue, respectively (13).
Neuronal nAChRs are distributed in numerous brain regions
and on both cell soma and dendrites, but it is the action of
nAChRs to modulate synaptic transmission presynaptically
that has received much attention recently (14, 16, 17). Selective
activation of distinct subtypes of these presynaptic nAChRs by
nicotinic agonists can regulate the release of different neuro-
transmitters, including dopamine, norepinephrine, glutamate,
GABA, and acetylcholine (14). To gain a better insight into the
role of the various nAChR subtypes in neurotransmission, ad-
ditional selective nAChR antagonists are required.
In this report we describe EpI, a novel conotoxin from the
molluscivorous C. episcopatus that targets the nAChR. The
peptide has the cysteine framework typical of a-conotoxins and
substantial sequence homology with the other a-conotoxins
isolated from non-piscivorous Conus species (see Table I). How-
ever, EpI differs from all previously reported a-conotoxins in
that it possesses a sulfotyrosine residue.
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MATERIALS AND METHODS
Isolation of EpI from Conus episcopatus
Five specimens of C. episcopatus (Fig. 1) were collected from The
Great Barrier Reef, Australia, dissected and an extract of crude venom
prepared from the pooled venom duct material as described previously
(18). Briefly, ground dried ducts were extracted with 30% acetonitrile/
water acidified with 0.1% trifluoroacetic acid, centrifuged, and the
supernatants lyophilized (yield 84 mg) and stored at 220 °C prior to
HPLC separation.
Isolation and Purification of EpI
Crude venom (4.4 mg) was fractionated by preparative reversed-
phase HPLC (Waters) using a 10-mm Vydac C18 column (1.0 3 25 cm)
eluted at 2.5 ml/min with a linear gradient from 0 to 80% B over 80 min:
solvent A, 10% acetonitrile, 0.1% trifluoroacetic acid; solvent B, 90%
acetonitrile, 0.09% trifluoroacetic acid. Absorbance was monitored at
214 and 280 nm. A major peak eluting at ;20 min was further purified
by analytical reversed-phase HPLC using a 5-mm Vydac C18 column
(0.46 3 25 cm) eluted at 1 ml/min with a linear gradient of 0 to 50% B
over 45 and 90 min. Absorbance was monitored at 214 nm.
Primary Structure of EpI
A sample of approximately 100 pmol of purified native peptide was
fully reduced in the presence of 50 mM dithiothreitol and 50 mM am-
monium acetate, pH 8.5, at 37 °C for 1 h, then alkylated in the presence
of 100 mM 4-vinylpyridine for 1 h at room temperature in the dark. The
alkylated peptide was repurified by HPLC and analyzed by Edman
chemistry on an ABI model 470A protein sequencer.
Sulfotyrosine Analysis of EpI
Enzymatic Treatment—A hydrolysate of EpI was prepared by car-
boxypeptidase Y digestion. Briefly, a sample of ;2 nmol of native EpI
was dissolved in 100 ml of 50 mM ammonium acetate, pH 5.5, and
treated with 0.75 mg of carboxypeptidase Y (Boehringer Mannheim,
sequencing grade) for 24 h at room temperature (enzyme to protein
ratio ; 1:5). The products of the enzymatic degradation were assessed
by analytical C18 HPLC, mass spectrometry (MS), and amino acid
analysis.
Preparation of Sulfated Tyrosine Standard—Sulfated Fmoc-Tyr was
treated overnight in mild sodium hydroxide. The reaction mixture was
purified on a 5 mM Vydac C18 reversed-phase column (0.46 3 25 cm).
With a standard gradient of 0.1% trifluoroacetic acid/acetonitrile, sul-
fated tyrosine eluted cleanly in the solvent front, while the remaining
reaction products were retained on a C18 column. Purity of the sulfated
tyrosine (262 Da) was confirmed by MS.
Derivatization of Amino Acids with PITC and Analysis by HPLC—
The free amino acids liberated from the digested peptide and amino acid
standards were derivatized with PITC (19). The digests and standards
were redried after addition of 40 ml of ethanol/water/triethylamine
(2:2:1). The derivatization reagent consisted of ethanol/triethylamine/
water/PITC (7:1:1:1) which was made fresh daily. The dried samples
were resolubilized with 40 ml of derivatization reagent and the sealed
samples allowed to react for 30 min before drying under vacuum.
Derivatized amino acids were separated on a Pico-Tag column (Waters)
using a linear gradient from 0% B to 46% B over 18 min: solvent A, 0.14
M sodium acetate containing 0.05% (v/v) triethylamine and adjusted to
pH 6.35 with glacial acetic acid; solvent B, 60% acetonitrile/water.
Mass Spectrometry (MS)
Mass spectra were acquired on a PE-SCIEX API 111 triple quadru-
pole mass spectrometer (PE-SCIEX, Ontario, Canada) equipped with
an ion spray atmospheric pressure ionization source. Samples (20 ml)
were injected into a moving solvent (10 ml/min; 50% acetonitrile, 0.05%
trifluoroacetic acid) coupled directly to the ionization source via a fused
silica capillary interface (50 mm 3 50 cm). Sample droplets were ana-
lyzed in both the positive and negative ionization modes. The ions
entered the analyzer through an interface plate and subsequently
through an orifice (100–120 mm diameter) at declustering potentials
from 10 to 90 V in the positive ion mode, and at –50 V in the negative
ion mode. Full scan spectra were acquired over m/z 500–2200 in 0.2 Da
steps with a total scan time of 3 s.
To help determine if EpI was sulfated, MS spectra of native and
synthetic EpI, CCK-8 (a sulfated peptide standard) and MLP111 (a
phosphorylated peptide standard) were acquired over m/z 50–100. A
high declustering voltage of –220 V and negative ion detection were
used to confirm the presence of the sulfate and related ions. The de-
clustering potential is the orifice voltage less the reference voltage (R0),
which was 30 or –30 V in positive or negative ion modes, respectively.
HPLC/MS analysis of crude venom (20 ml of a 2 mg/ml solution) was
performed with a 5-mm Vydac C18 column (0.21 3 25 cm) eluted at 130
ml/min with 100% A for 2 min and then 0 to 80% B over 80 min: solvent
A, 0.05% trifluoroacetic acid; solvent B, 90% acetonitrile, 0.05% triflu-
oroacetic acid. Mass spectra were acquired over m/z 400–2200 at 0.2
Da steps, with a dwell time of 0.3 ms and a total scan time of 3.2 s.
Determination of Disulfide Connectivity
Native EpI (1 nM) was added to the reaction buffer (25 ml; 0.1 M
NH4OAc/acetonitrile, 90/10 (v/v); pH 4) and reacted with the reducing
agent Tris(2-carboxyethyl)phosphine (2:1, w/w). An aliquot (1 ml) was
injected into the MS to determine the extent of reduction over 2 to 10
min. This partially reduced EpI was reacted with 100 mM of the alky-
lating reagent maleimide (pH 4.0; 21 °C) over 5 min with 1-ml aliquots
injected into the MS to determine the extent of alkylation. A reaction
product representing the alkylation of one disulfide bond, as deter-
mined by MS, was isolated using reversed-phase gradient HPLC on a
5-mm Vydac C18 column (0.21 3 25 cm). To determine disulfide bond
connectivity of EpI, this partially reduced product was subjected to
Edman sequencing. Disulfide bond connectivity was also determined by
collision-induced dissociation MS. Collision-induced dissociation of the
partially reduced and alkylated parent precursor ion was effected by
bombardment with ultrapure Argon. Bombardment was carried out in
quadrupole-2 with a collision cell gas thickness of 3 3 1014 atoms/cm2
and a collision energy (Q-0 to Q-2 rod offset voltage) of typically 20–40
eV relative to the laboratory frame. The resulting product ion spectra
were obtained by scanning quadrupole-3 over m/z 50–2200 at 0.2 Da
steps. Spectra were analyzed with MacBioSpec (PE-SCIEX).
Peptide Synthesis
Chain Assembly—Two peptides, EpI and [Tyr15]EpI, were each syn-
thesized on a 0.5-mmol scale by manual solid phase peptide synthesis
using Fmoc chemistry. The following amino acid side chain protecting
groups were used: Arg(Pmc), Asn(Trt), Asp(OtBu), Cys(Trt), and
Ser(tBu). Met, Gly, and Pro, were used without side chain protection.
Sulfated tyrosine was used for the synthesis of EpI and Tyr(tBu) was
used for the synthesis of the unsulfated peptide ([Tyr15]EpI). Peptide
resin samples (;5 mg) were removed after each coupling step for
determination of residual free a-amino groups by the quantitative nin-
hydrin test (20), except for couplings to proline where a coupling effi-
ciency of .99.5% was assumed where the result of a modification of the
Isatin test (21, 22) was satisfactory. Double couplings were used to
achieve coupling efficiencies of .99.5%. First couplings ,95% were
obtained only for residues 8 and 9 of [Tyr15]EpI.
Deprotection, Cleavage, and Peptide Oxidation—The Na-Fmoc group
was removed on resin from the fully protected peptide by treatment
with piperidine/dimethylformamide (1:1, 2 3 1 min) and the partially
deprotected peptide resin was dried under a stream of nitrogen after
washing with dimethylformamide and dichloromethane. The peptide
was cleaved from the resin and the side chain protecting groups were
simultaneously removed by treatment with (i) trifluoroacetic acid/H2O
(9:1, v/v) with 50 eq of m-cresol or (ii) trifluoroacetic acid/triisopropyl-
silane (9:1, v/v) (33), both at 4 °C for 3 to 5 h with similar results. The
majority of the trifluoroacetic acid was removed on a rotavapor and the
crude peptide precipitated, washed with ether, dissolved in 50% aceto-
nitrile, 0.1% trifluoroacetic acid, diluted with water, and lyophilized.
The peptide precipitation, washing, and dissolution steps were carried
out under a stream of nitrogen to minimize uncontrolled air oxidation of
the peptide. The peptides were purified by reversed-phase HPLC and
FIG. 1. C. episcopatus, a molluscivorous Conidae (length 8 cm)
collected from the Great Barrier Reef, Australia.
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the purified reduced peptides (100 mM) were oxidized in 100 mM
NH4HCO3, pH 8.3, at room temperature for 24–48 h.
Purification of Synthetic EpI and [Tyr15]EpI—Synthetic peptide ox-
idation was monitored by analytical reversed-phase HPLC on a 5-mm
Vydac C18 column (0.46 3 25 cm). EpI and [Tyr15]EpI were obtained
using a preparative 10-mm Vydac C18 column (2.2 3 25 cm) eluted at 8
ml/min with 5 to 50% B over 60 min and 50 to 80% B over 20 min:
solvent A, 0.1% trifluoroacetic acid; solvent B, 90% acetonitrile, 0.09%
trifluoroacetic acid. The eluant was monitored at 230 nm. Retention
times of native and synthetic peptides were compared by analytical
reversed-phase HPLC (see above) eluted at 1 ml/min with a linear
gradient of 0.7% acetonitrile/min from 0.1% trifluoroacetic acid to 90%
acetonitrile, 0.09% trifluoroacetic acid. Coelution was confirmed by
co-injection of synthetic and native EpI in a 2:1 ratio.
Materials for Peptide Characterization and Synthesis
Acetonitrile, ethanol, and glacial acetic acid were from BDH Labo-
ratory Supplies, Poole, United Kingdom. High purity water was gener-
ated by a Milli-QTM purification system (Millipore, Bedford, MA). Tri-
ethylamine (freshly distilled) was from Sigma. Phenylisothiocyanate
(PITC) and amino acid standards were from Pierce. Sodium acetate was
from Aldrich Chemical Co. 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetram-
ethyluronium hexafluorophosphate, piperidine, trifluoroacetic acid, di-
isopropylethylamine, dimethylformamide (peptide synthesis grade),
and Fmoc-sulfotyrosine were purchased from Auspep (Melbourne, Aus-
tralia). Acetonitrile (HPLC grade) was obtained from Waters Millipore
(Milford, MA). Fmoc-aa-resin (Ramage Amide-Resin, tricyclic amide
linker) was purchased from BAChem and Fmoc-L-amino acids were
purchased from BAChem, Nova Biochem, and Auspep. Stock solutions
(100 mM) of Tris(2-carboxyethyl)phosphine (Strem Chemicals), maleim-
ide (Aldrich), 4-vinylpyridine and dithiothreitol were prepared in 90:10
(v/v) 0.1 M NH4OAc/acetonitrile, pH 4.0, and stored at –20 °C. Other
reagents and solvents were ACS analytical reagent grade.
Measurement of Catecholamine Secretion from Chromaffin Cells
Chromaffin cells were isolated from bovine adrenal medullary tissue
and cultured as described previously (23). The protocol employed for the
catecholamine release studies was that detailed by Livett et al. (24).
Experiments were conducted on 24-well culture plates containing 0.4
ml of medium/well at 1.25 3 106 cells/ml. Following a 3-day incubation
at 37 °C in an atmosphere of 10% carbon dioxide, the culture was
allowed to equilibrate to room temperature for 5 min. To remove the
incubation medium, the culture was washed with modified Locke’s
buffer of the following composition in mM: NaCl, 154; KCl, 2.6; CaCl2,
2.2; K2HPO4, 2.15; KH2PO4, 0.85; MgSO4, 1.18; D-glucose, 10; and
bovine serum albumin, 0.5%. The cells were preincubated in the pres-
ence or absence of synthetic conotoxin (0–10 mM) for 5 min at room
temperature and then incubated for 5 min with 4 mM nicotine 6 cono-
toxin. Cells treated with buffer alone, 4 mM nicotine alone, or conotoxin
alone served as controls. The incubation medium containing released
catecholamines was removed and acidified with 2 M perchloric acid. To
determine total cell catecholamines, the cells in each culture plate well
were treated for 5 min with 0.01 M perchloric acid to lyse the cells and
acidified to a final concentration of 0.4 M perchloric acid. The released
catecholamines were quantified by electrochemical oxidation, after sep-
aration by reverse-phase HPLC (24). For K1-induced catecholamine
release experiments, 56 mM KCl was used as the agonist instead of
nicotine. In the nicotine/conotoxin competition experiments, the cells
were incubated with synthetic EpI or [Tyr15]EpI at 1 mM and varying
concentrations of nicotine (0–100 mM).
Rat Phrenic Nerve-Hemidiaphragm Studies
Male Buffalo rats (150–250 g, 3–4 months old) were sacrificed by
asphyxiation with carbon dioxide and exsanguinated. The left hemi-
diaphragm and phrenic nerve were isolated as described previously (25)
and mounted under 1 g of resting tension in a 25-ml organ bath
containing Krebs-Henseleit solution aerated with carbogen (95% O2, 5%
CO2). The nerve was stimulated via a bipolar electrode with pulses of
0.5-ms duration and supramaximal voltage using a Grass S48 stimu-
lator with an SIU5 isolation unit. Single twitches were produced by
continuous stimulation at 0.1 Hz, interspersed at 5-min intervals by
train-of-four twitches (2 Hz for 1.9 s) or tetanic contractions (50 Hz for
2 s), measured alternately. Responses were detected using a Grass
FT03 isometric force-displacement transducer connected to a Neotrace
DC amplifier and recorded via a Mac Lab/4S using the application
Chart (v 3.4/s) on a Macintosh LC630 computer. The tissue was treated
with synthetic conotoxin (1–10 mM) in buffer for 60 min, washed several
times with buffer alone, and then allowed a 30-min recovery time prior
to treatment with the next higher toxin concentration. Data analyses
were performed as described previously (26).
Acetylcholine-evoked Currents in Rat Parasympathetic Neurons
Preparation—Membrane currents were studied in isolated parasym-
pathetic neurons of neonatal rat intracardiac ganglia. The procedures
for isolation of these neurons have been described in detail previously
(27). Briefly, neonatal rats (3–8 days old) were sacrificed by decapita-
tion, and the heart was excised and placed in a saline solution contain-
ing (mM): 140 NaCl, 3 KCl, 2.5 CaCl2, 0.6 MgCl2, 7.7 glucose, and 10
HEPES (pH adjusted to 7.2 with NaOH). Atria were removed and
incubated for 1 h at 37 °C in saline solution containing 1 mg/ml colla-
genase (Type 2; Worthington Biochemical Corp., Freehold, NJ). Follow-
ing enzymatic treatment, clusters of ganglia were dissected from the
epicardial ganglion plexus, transferred to a sterile culture dish contain-
ing high glucose culture medium (Dulbecco’s modified Eagle’s medium),
10% (v/v) fetal calf serum, 100 units/ml penicillin, and 0.1 mg/ml strep-
tomycin, and triturated using a fine-bore Pasteur pipette. The dissoci-
ated neurons were then plated onto 18-mm glass coverslips coated with
laminin, and incubated at 37 °C for 24–72 h under 95% air, 5% CO2, in
a humid atmosphere. At the time of the experiments, neurons were
transferred to a recording chamber (0.5-ml volume) and viewed at
400 3 magnification using an inverted phase-contrast microscope.
Electrical Recordings and Data Analysis—Membrane currents were
recorded from isolated intracardiac neurons under voltage clamp con-
ditions using the whole-cell patch recording configuration (28). In
whole-cell experiments, electrical access was achieved either by ruptur-
ing the membrane patch and dialyzing the cell, or through the use of the
perforated patch method (29). The perforated patch method allows the
intracellular integrity of the neurons to be maintained to confirm that
any effects are independent of possible cell dialysis effects which can
alter the functional response of these neurons (30).
For perforated patch experiments, a stock solution of 60 mg/ml am-
photericin B in dimethyl sulfoxide was prepared the day of the exper-
iment and kept on ice, in the dark. Immediately prior to use, the
amphotericin B stock solution was diluted in pipette solution (see be-
low) to yield a final concentration of 360 mg/ml amphotericin B in 0.6%
dimethyl sulfoxide. Following gigaseal formation, the neurons were
held at –70 mV and voltage pulses (20 ms) to –80 mV were applied at
1 Hz. Amphotericin B incorporation into the membrane patch resulted
in a fast capacitive transient, the appearance of a slow capacitive
transient and a decrease in the series resistance (RS). Experiments
were continued only if RS decreased to #10 megohm within 10 min of
seal formation. Final series resistance was usually 5–8 megohm, and
approximately 50% RS compensation was used.
Electrodes for whole-cell experiments were pulled from thin-walled
borosilicate glass (TF150; Clark Electromedical Inst., Reading, United
Kingdom) and the final pipette resistance was 1–3 megohm for conven-
tional and perforated patch whole-cell recording. Membrane currents
evoked by agonist application were amplified and filtered (5 kHz) using
and Axopatch 200A patch clamp amplifier (Axon Instruments Inc.,
Foster City, CA) and recorded on DAT tape using an analog to digital
tape recorder (DT-1204; Biologic, Claix, France). Membrane currents
were continuously monitored on a digital oscilloscope and a chart re-
corder. For computer analysis, acetylcholine (ACh)-evoked currents
were played back from digital tape, filtered, and digitized (Digidata
1200A; Axon Instruments Inc.). Whole-cell currents were filtered at 1
kHz (–3 dB; 4-pole Bessel filter), sampled at 3 kHz and acquired to a PC
Pentium/100 MHz computer using the Axoscope 1.0 and pClamp 6
acquisition programs (Axon Instruments Inc.). Data are expressed as
mean 6 S.E.
The control external solution for dialyzed and perforated whole-cell
recordings was physiological saline solution containing (mM): 140 NaCl,
3 KCl, 2.5 CaCl2, 1.2 MgCl2, 7.7 glucose, and 10 HEPES-NaOH, pH 7.2.
The pipette solution for conventional whole-cell recordings consisted of
(mM): 140 CsCl, 2 MgATP, 0.2 guanosine 59-triphosphate sodium salt
(GTP), 2 Cs4BAPTA, 10 HEPES-CsOH, pH 7.2. The perforated patch
pipette solution contained (mM): 75 K2SO4, 55 KCl, 5 MgSO4, 10 HEPES
(pH to 7.2 with N-methyl-d-glucamine). The recording chamber was
continuously perfused (2 ml/min) with the indicated solutions at room
temperature (22–23 °C). ACh-evoked responses were elicited during
whole-cell recordings by focal and rapid application of 500 mM ACh 6
synthetic EpI or [Tyr15]EpI in physiological saline solution containing
100 nM atropine from a multibarrel flow pipe mounted on a piezoelectric
positioning system (PZS-200; Burleigh Instruments, Inc., Fishers, NY).
Atropine (0.1–1 mM) was added to both the bath and solutions through
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the multibarrel flow pipes to inhibit muscarinic receptor-mediated cur-
rents observed in perforated-patch whole-cell recordings (30). The flow
pipe constructed from u-tubing was positioned 50 mm from the cell soma
to evoke maximal responses to ACh. The osmotic activities of the
solutions were monitored with a vapor pressure osmometer (Wescor
5500).
Materials for Chromaffin Cell Culture and
Parasympathetic Neuron Studies
For chromaffin cells, culture media, penicillin (G, sodium, NF grade),
streptomycin sulfate, and fetal calf serum were obtained from Life
Technologies, Inc. Collagenase A was from Boehringer-Mannheim and
Percoll from Pharmacia. Tissue culture plates were from Sarstedt.
Bovine serum albumin was from HA¨MOSAN, perchloric acid and buffer
salts were from BDH Chemicals Ltd., and all stock solutions were
prepared in Locke’s buffer and stored at –20 °C. For rat parasympa-
thetic neuron studies, all chemical reagents were analytical grade. ACh,
atropine sulfate, and mecamylamine hydrochloride were from Sigma
and a-bungarotoxin was from Calbiochem (La Jolla, CA).
RESULTS
Isolation and Chemical Characterization of EpI
Identification of EpI—Most a-conotoxins identified to date
have two disulfide bonds, fall within the mass range 1300–
2000 Da, and elute at relatively low concentrations of organic
solvent on reversed-phase chromatography. HPLC/MS (Fig.
2A) and HPLC (not shown) of a crude extract from C. episco-
patus revealed a major, early eluting peak (at 22 or 19 min by
analytical or preparative HPLC, respectively) that was identi-
fied as a new conopeptide we named EpI. EpI was present in
the crude venom at 1–5% of the A214 absorbing material.
Selected scans from two HPLC/MS runs at different declus-
tering potentials of 15 and 50 V are shown in Fig. 2, B and C.
At the lower declustering potential, two coeluting masses dif-
fering by 80 Da were observed, while at higher declustering
potentials the lower mass predominated. These spectra, to-
gether with the observation of a reduced tendency to lose 80 Da
when analyzed in negative ion detection mode (31), suggested
EpI was a sulfated peptide of average molecular mass 1866.6
Da. Further confirmation of the presence of a sulfated amino
acid being present in EpI was obtained using a high decluster-
ing potential (–220 V) and negative ion detection. The resultant
mass spectrum revealed the presence of characteristic sulfate
ions, SO3
2 and SO4
2 at m/z 80 and 96, respectively (data not
shown). Comparison of the spectra of EpI to those of CCK-8 (a
sulfated peptide) and MLP 111 (a phosphorylated peptide) con-
firmed that EpI was sulfated (data not shown).
Primary and Secondary Structure of EpI—Purified EpI was
reduced, alkylated, and its sequence determined by Edman
sequencing to be GCCSDPRCNMNNPDYC. This sequence
gave the predicted relative molecular mass (Mr) of 1787.02 Da
for the oxidized, COOH-terminally amidated form, 80 Da less
than molecular mass 1867.08 Da predicted for the sulfated
peptide. Disulfide connectivity was determined by partial re-
duction, alkylation, and Edman sequencing. EpI was found to
have the conserved a-conotoxin framework [1–3, 2–4] with
disulfide linkages between Cys2–Cys8 and Cys3–Cys16. MS in-
dicated that the carboxyl terminus was amidated, assuming
one residue was sulfated (data not shown). MS also showed
that residues at positions 2 and 8 had been selectively alky-
lated and that EpI possessed two disulfide bonds (data not
shown).
Identifying the Post-translational Modification—Reduced
and alkylated EpI was cleaved with trypsin to generate two
fragments which were analyzed by MS and further fragmented
by MS/MS to help locate the site of the 180 Da modification.
This showed that the modification was in the COOH-terminal
fragment, most likely at Tyr15 (data not shown). EpI was also
digested with carboxypeptidase Y to generate an enzymic hy-
drolysate and, after treatment of the hydrolysate with PITC,
amino acid analysis of this material showed that the tyrosine
residue was sulfated (Fig. 3).
Synthesis of EpI and [Tyr15]EpI—Solid phase chemical syn-
thesis of EpI was undertaken to confirm the proposed structure
of EpI and to provide sufficient material for further biological
(present study) and structural characterization.2 The cleavage
conditions selected to remove reduced EpI from resin were a
compromise between achieving adequate removal of the side
chain protecting groups and preventing undesirable desulfa-
tion. Problems were encountered with the incomplete removal
of the tBu and Pmc protecting groups. Unfortunately, the use of
1,2-ethanedithiol to scavenge tBu and thioanisole to accelerate
Arg(Pmc) deprotection by trifluoroacetic acid is incompatible
with sulfopeptide synthesis (33). Oxidation of pure reduced EpI
resulted in the production of one major isomer and two minor
isomers. The major oxidized product, which eluted earlier than
the reduced form, was purified by reversed-phase HPLC and
compared with native EpI. MS results were consistent with the
amidated form (synthetic EpI calculated Mr 1867.08 Da, ob-
served molecular mass 1866.6 Da). Oxidized synthetic EpI
coeluted with the native EpI peptide (Fig. 4). HPLC chromato-
grams (Fig. 4) and MS analyses (data not shown) confirmed the
2 S.-H. Hu, M. Loughnan, R. Miller, C. M. Weeks, R. H. Blessing, P. F.
Alewood, R. J. Lewis, and J. L. Martin, unpublished data.
FIG. 2. Identification of EpI. A, base peak chromatogram obtained
from a HPLC/MS of the crude venom of C. episcopatus (m/z 400–2200,
declustering potential 50 V). B, MS spectrum of EpI from HPLC/MS at
a declustering potential 15 V, with an inset showing the reconstructed
spectrum. C, MS spectrum of EpI from A at a declustering potential 50
V, with an inset showing the reconstructed spectrum.
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purity of native and synthetic EpI and synthetic [Tyr15]EpI.
Using a similar protocol, the analogue [Tyr15]EpI yielded one
predominant isomer and two minor isomers. The purified un-
sulfated analogue [Tyr15]EpI eluted slightly later than the
sulfopeptide EpI. MS gave a result consistent with [Tyr15]EpI
(calculated Mr 1787.02 Da, observed molecular mass 1786.2
Da).
Mode of Action of EpI
Muscle-type Nicotinic Acetylcholine Receptor Response—Syn-
thetic EpI and [Tyr15]EpI were tested in the rat phrenic nerve-
hemidiaphragm preparation (26). Neither peptide significantly
inhibited single twitches, train-of-four twitches, or tetanic con-
tractions after incubation for 1 h over the concentration range
1–10 nM (data not shown).
Neuronal-type Nicotinic Acetylcholine Receptor Response—
Synthetic EpI and [Tyr15]EpI inhibited nicotine-induced cate-
cholamine release in bovine chromaffin cells (Fig. 5). EpI in-
hibited 50% of nicotine-induced adrenaline and noradrenaline
release at 8.4 3 1028 M and 2.1 3 1027 M (pIC50 6 S.E. values
of 7.1 6 0.12 M and 6.7 6 0.06 M), respectively. [Tyr15]EpI was
less potent, inhibiting nicotine-induced adrenaline and nora-
drenaline release at 8.5 3 1027 M and 1.0 3 1026 M (pIC50
values of 6.1 6 0.1 M and 6.0 6 0.08 M), respectively. Hill slopes
obtained for these inhibitory dose-response curves ranged from
–0.6 to –0.7, with 95% confidence intervals ranging from –0.8
to –0.4, indicating slopes significantly different from –1. Both
EpI and [Tyr15]EpI appear to be full functional antagonists of
nicotine-evoked noradrenaline and adrenaline release (Fig.
5A). K1-induced catecholamine release was not inhibited by
either peptide up to 10 mM (data not shown), indicating that the
inhibition by EpI of nicotine-evoked catecholamine secretion
was via inhibition at the nAChRs, rather than by block of the
voltage-gated ion channels.
Addition of EpI (1 mM) with various concentrations of nicotine
(0–100 mM) resulted in a parallel shift of the nicotine dose-
response curve to the right (Fig. 5B). [Tyr15]EpI caused a
similar shift in the nicotine dose-response curve (data not
shown). These observations are consistent with EpI and
[Tyr15]EpI acting as functional competitive inhibitors of nico-
tine action at the nAChR.
ACh-evoked Membrane Currents in Rat Parasympathetic
Neurons—To further investigate the effects of synthetic EpI on
neuronal AChRs, whole-cell recording of membrane currents
evoked in response to rapid application of ACh was carried out
in isolated parasympathetic neurons from rat intracardiac gan-
glia. ACh-evoked currents obtained in response to 500 mM ACh
in a neuron held at –60 mV are shown in Fig. 6 (control traces).
ACh-evoked peak current amplitude was substantially larger
than previously reported in these neurons (27, 30, 34) due to
the rapid application of ACh minimizing nicotinic ACh receptor
desensitization (35). ACh-evoked currents were completely and
reversibly inhibited by bath application of 1 mM mecamylamine.
In the presence of 1 nM EpI, the ACh-evoked current amplitude
was reversibly decreased by 24% but the kinetics of the re-
sponse appeared unchanged (Fig. 6A). The percentage inhibi-
tion of ACh-evoked current observed over the voltage range
–120 to –20 mV was similar, indicating that the block at the
nicotinic AChR was not voltage dependent. Bath application of
300 pM [Tyr15]EpI similarly reduced the amplitude of the ACh-
evoked current by 27% and its effect was reversible upon wash-
out (Fig. 6B). Fig. 6C shows inhibition of ACh-evoked currents
obtained in the presence of a maximal effective concentration of
EpI (300 nM) or 300 nM [Tyr15]EpI in the same neuron. The
EpI-resistant current obtained in the presence of both EpI and
[Tyr15]EpI exhibited an increased rate of decay and was abol-
ished by mecamylamine (1 mM) or a-bungarotoxin (1 mM). Dose-
response relations obtained for the inhibition of ACh-evoked
current amplitude at –60 mV in the presence of EpI and
[Tyr15]EpI are shown in Fig. 6D. The dose-response relations
were fitted with a single site adsorption isotherm with half-
maximal inhibitory concentrations (IC50) of 1.6 and 0.4 nM for
EpI and [Tyr15]EpI, respectively. Maximal inhibition obtained
FIG. 4. Analytical reverse phase HPLC comparison of native
and synthetic EpI and [Tyr15]EpI. A, native EpI; B, synthetic EpI; C,
co-injection of synthetic plus native EpI in a 2:1 ratio; D, synthetic
[Tyr15]EpI. Detection at 214 nm and retention time in minutes.
FIG. 3. Modified amino acid analy-
sis of sulfated tyrosine (PTC deriva-
tives detected). A, native EpI hydroly-
sate generated by carboxypeptidase Y
digestion; B, analysis blank; C, sulfated
tyrosine standard.
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with EpI and [Tyr15]EpI concentrations up to 1 mM was 60% of
the peak ACh-evoked current. The EpI-resistant current was
observed in the majority (.80%) although not all neurons
studied, and was blocked by a-bungarotoxin.
DISCUSSION
We have isolated and characterized a new a-conotoxin, EpI,
from the venom of the molluscivorous snail C. episcopatus
collected from the Great Barrier Reef, Australia. The peptide
was classified as an a-conotoxin based on sequence, disulfide
connectivity, and pharmacology. a-Conotoxin EpI is the first
sulfated conotoxin characterized. The sulfate, which is on Tyr15
of EpI, is almost completely lost at declustering potentials used
routinely for the MS analysis of peptides ($40 V), making its
detection difficult. However, the sulfotyrosine could be identi-
fied by amino acid analysis and MS at low declustering poten-
tials or in negative ion detection mode (31). The coelution of
native and synthetic EpI support our direct evidence that EpI
was sulfated at Tyr15. Interestingly, no [Tyr15]EpI was de-
tected in the venom of C. episcopatus.
While extensive post-translational modifications are charac-
teristic of conopeptides, phosphorylation or sulfation in cono-
toxins has not previously been demonstrated. However, the
possible presence of sulfated and/or phosphorylated derivatives
of PnIB has been suggested on the basis of a mass difference of
80 Da in unconfirmed observations of Fainzilber et al. (36).
Tyrosine sulfation has been recognized as a widespread post-
translational modification of proteins and consensus features
of tyrosine sulfation sites have been described (37, 38). The
known tyrosine-sulfated proteins can be classified into discrete
functional classes including blood clotting factors, neuropep-
tides, extracellular matrix proteins, and immune system pro-
teins (37). A recent revision of the consensus features for tyro-
sine O-sulfation based on mutational analysis experiments
found, contrary to previous findings (i) that neighboring resi-
dues contribute only moderately to sulfation and (ii) that ex-
tensive sulfation can be obtained despite dramatic changes in
the charge distribution of the neighboring residues, with basic
residues not only being permissible near the site of sulfation
but perhaps enhancing sulfation (39). The single critical posi-
tion for tyrosine O-sulfation is 21, which should contain a
neutral or acidic residue. EpI fulfils these requirements. An-
other suggested consensus feature for tyrosine sulfation is the
absence of disulfide-bonded cysteine residues from –7 to 17
(37, 38). EpI clearly does not fit this criterion, possessing a
disulfide-bonded cysteine residue at –7 and 11. However, there
is no direct evidence that disulfide bonds necessarily prevent
the sulfation of tyrosine (38). EpI may be the first example of
this motif. The functional role of sulfation in this a-conotoxin is
less clear. Aside from any effect on potency or selectivity, sul-
fation may have evolved as a strategy to improve the in vivo
stability of conotoxins. However, reports in the literature are
equivocal. Differential behavior of sulfated and unsulfated pep-
tides has been observed in studies of the degradation of human
gastrin and cholecystokinin by endopeptidase, where the pres-
ence of a sulfate group reduced the rate of hydrolysis of gastrin
by endopeptidase, yet enhanced cholecystokinin degradation
by the same enzyme (40).
EpI is constructed with 4 residues in loop one and 7 residues
in loop two and was anticipated to have a structure similar to
those reported for PnIA and PnIB (41, 42). Compared with
other 4/7 framework a-conotoxins, EpI has homology to both
loop one and loop two of PnIA and PnIB and to loop one of MII
(see Table I). The a-conotoxins EpI, MII (10, 43, 44), PnIA,
PnIB (36), and ImI (9, 43, 45) all contain 4 amino acid residues
in loop one, the first of which is serine, suggesting that this
construct may be important for neuronal nAChR selectivity.
The crystal structure of [Tyr15]EpI and a detailed comparison
with PnIA and PnIB are reported elsewhere.2
The activities of synthetic EpI and its unsulfated analogue
[Tyr15]EpI were similar. Both caused competitive inhibition of
nicotine-induced catecholamine release in bovine adrenal chro-
maffin cells (predominantly neuronal a3b4 nAChRs (46)) but
neither had an effect on the rat phrenic nerve-hemidiaphragm
(muscle nAChRs). Thus EpI and [Tyr15]EpI are selective inhib-
itors of neuronal nAChRs. At nanomolar concentrations, both
peptides partially inhibited ACh-evoked currents in a dose-de-
pendent manner in isolated parasympathetic neurons of rat
intracardiac ganglia. The EpI block of nAChRs was reversible
and did not exhibit any voltage dependence. The residual cur-
rent that remained after saturating doses of EpI or [Tyr15]EpI
was found to be sensitive to inhibition by a-bungarotoxin, in-
dicating that EpI has little, if any, effect on neuronal a7
nAChRs of rats. Given that the remainder of the ACh-evoked
current in rat parasympathetic neurons arises from nAChRs
constructed primarily of a3b2 and/or a3b4 subunits (47), it
appears that EpI selectively inhibits neuronal a3b2 and a3b4
nAChRs. The difference in the rank order of potency between
EpI and [Tyr15]EpI at bovine chromaffin cells and rat parasym-
pathetic neurons may indicate that sulfation has an effect on
selectivity across rat and bovine nAChRs. It is possible that
EpI may have evolved to selectively target molluscan forms of
the nAChR as part of the prey capture strategy of C. episcopa-
tus. The more than 50-fold difference in absolute potency be-
tween EpI and [Tyr15]EpI at bovine chromaffin cells and rat
FIG. 5. Synthetic EpI and [Tyr15]EpI inhibition of the nicotine-
evoked catecholamine release in bovine chromaffin cells. A,
concentration-dependent conotoxin inhibition of 4 mM nicotine-stimu-
lated adrenaline (Ad) and noradrenaline (NA) release over 5 min (n 5
3–4). Neither conotoxin inhibited 56 mM K1-induced release (data not
shown). B, effect of EpI on the concentration-dependent nicotine-in-
duced release of noradrenaline, expressed as a percentage of total cell
noradrenaline (n 5 3–4). EpI caused a parallel shift in the response
indicative of functional competitive antagonism. Similar results were
obtained for noradrenaline release and for the effect of [Tyr15]EpI on
both adrenaline and noradrenaline release (data not shown).
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parasympathetic neurons is not unexpected given results of
other investigators with the more sensitive patch-clamp tech-
nique. For example, a-conotoxin ImI has an IC50 of 0.22 mM in
patch-clamp studies on frog oocytes (45) compared with 3.0 mM
in bovine chromaffin cells (43). Species differences in the sus-
ceptibility of muscle- and neuronal-nicotinic receptors to
a-conotoxins have also been noted for a-conotoxins MI (44) and
ImI (9).
With respect to its ability to inhibit nAChRs in bovine chro-
maffin cells, EpI is the most potent of the a-conotoxins tested to
date, being 5-fold more potent than PnIB (IC50 5 0.7 mM) and
20-fold more potent than ImI (IC50 5 3 mM) (43). It is unlikely
that EpI targets bovine a7 receptors, given that EpI inhibits
both adrenaline and noradrenaline secretion in bovine chro-
maffin cells but only the adrenaline cells contain a7 (49). Fur-
thermore, studies in the rat parasympathetic intracardiac gan-
glia indicate that EpI has little if any effect on rat neuronal a7
nAChRs. It has previously been shown that a-conotoxin MII
specifically targets rat a3b2 nAChRs (10, 44), whereas we show
here that EpI and [Tyr15]EpI likely target rat a3b2 and a3b4.
On the basis that Campos-Caro et al. (46) have shown that
there is no b2 subunit expressed in bovine chromaffin cells
(which contain neuronal a3, a5, a7, and b4 subunits) it appears
that EpI targets bovine a3b4 receptors. However, there is phar-
macological evidence that a3b4 in bovine chromaffin cells be-
haves similarly to a3b2 in the rat (46, 50).
Our findings with EpI reinforce those of Groebe et al. (48)
with MI who suggest that caution should be exercised when
a-conotoxins are used to pharmacologically define the nicotinic
receptor subtypes across different species. A radioligand bind-
ing assay utilizing [125I-Tyr15]EpI to more precisely define its
site of binding in different species is under development. The
recent finding of Kulak et al. (14) shows that a-conotoxins with
appropriate nAChR-subtype specificity have potential as novel
therapeutics. Given that its structure is now well defined,2 EpI
provides a useful template for the design of selective small
molecule inhibitors of neuronal nAChRs.
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